Close Menu

NEW YORK — German molecular diagnostics firm Epigenomics on Thursday said its second quarter revenues declined 76 percent year over year, primarily due to the effects of the COVID-19 pandemic.

For the three-month period ended June 30, Epigenomics revenues fell to €83,000 ($98,204) from €348,000 in the year-ago quarter. The company attributed the decline to the almost complete loss of revenues in its US business because of COVID-19.

The company's Q2 product revenues declined 78 percent to €73,000 from €339,000 a year ago.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.